Navigation Links
Phase Genomics Announces Commercial Availability of Rapid End-to-End Genome Assembly Service
Date:1/14/2017

Seattle-based Phase Genomics has announced the general availability of Proximo™, a new service providing complete end-to-end genome assemblies to researchers around the globe. Long considered a “holy grail” in biological research, access to complete genomes eliminates a major obstacle in answering a wide range of scientific questions. The announcement was made today at the Plant & Animal Genome Conference (PAGXXV) in San Diego.

“After receiving very positive responses from our initial customer engagements, we are thrilled to bring this solution to the broader market.” said Dr. Ivan Liachko, CEO and Co-founder of Phase Genomics. “We believe Proximo represents a fundamental advancement in genome assembly technology that will help researchers in a variety of fields.”

Creating a complete or “chromosome-scale” reference genome for an organism is akin to completing the genetic blueprint for that species. Previously, most genome sequencing and assembly technologies left genomes in many pieces, obscuring significant information about the biology of an organism. Making a complete genome requires grouping and arranging hundreds or thousands of DNA sequences properly, a highly laborious, expensive, nearly impossible task with traditional tools. In practice, these assembly methods leave most genome assemblies highly fragmented, much like unfinished jigsaw puzzles.

To overcome this obstacle, Phase Genomics developed a new approach to measure the distances between DNA sequences using a modified version of the popular chromosome conformation capture method, Hi-C. These measurements allow the company’s software to organize DNA sequence fragments into whole chromosomes.

“We had tried all of these other genome assembly technologies,” said Prof. Mitch McGrath of Michigan State University, who studies sugar beets and agricultural productivity. “Then Phase Genomics used Proximo at the final step to make 9 complete scaffolds for 9 sugar beet chromosomes – exactly where I wanted to be. I almost fell off my chair when I saw it. It’s very exciting.”

Interested parties can learn more about Proximo and other Phase Genomics services by visiting their booth at the Plant & Animal Genome Conferece (PAGXXV) or by visiting Phase Genomics their website at http://www.phasegenomics.com.

Read the full story at http://www.prweb.com/releases/2017/01/prweb13984457.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Symbios Announces National Science Foundation SBIR Phase IIB Award to Commercialize Plasma Oxidation Technology
2. Vtesse Announces Dosing of First Patient in Australia in Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease
3. Recombinant Technologies, LLC, Receives Phase II SBIR Grant to Develop AmyTrap for Treatment of Alzheimer’s Disease
4. AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension
5. Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
6. Soligenix Announces Investor Webcast Event: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis
7. ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 Conference
8. Nordion and General Atomics Welcome US National Nuclear Security Administration Phase II Funding for New, Reliable Source of Molybdenum-99
9. Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis
10. Axovant to Present Patient Function and Independence Data Analyses from Phase 2b Study of Investigational Treatment Intepirdine in Alzheimers Disease at CTAD 2016
11. Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... a United States multicenter, prospective clinical study that demonstrates the accuracy of ... capable of identifying clinically significant acute bacterial and viral respiratory tract infections ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality ... Several trends in analytical testing are being attributed to new regulatory requirements for ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):